Loading
Every dated change on the records linked to Ductal carcinoma in situ (DCIS), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Active monitoring with mammography every six months and optional endocrine therapy, in trials (COMET, LORIS, LORD) or after shared decision-making where guidelines allow.
At two years the rate of ipsilateral invasive cancer with active monitoring was non-inferior to guideline-concordant surgery.
Hwang and colleagues (JAMA, December 2024); first randomised evidence for monitoring low-risk DCIS.
10-year ipsilateral breast tumour recurrence 4.
Eight-year ipsilateral breast tumour recurrence 3.
Tamoxifen 5 mg daily for three years roughly halved breast cancer events compared with placebo with few serious adverse effects.
Lumpectomy to 2 mm margins followed by whole-breast radiotherapy (hypofractionated), with radiotherapy omission considered for low-risk lesions (RTOG 9804 criteria or genomic assay). (NCCN Category 1 (radiotherapy after lumpectomy))
A milestone in how this cancer is treated.